Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer — PILOT

Non-small-cell Lung Cancer (NSCLC) Clinical Trial

Official title:
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Newly Diagnosed Stage Ⅲ Unresectable Non-small Cell Lung Cancer: a Open-label, Single-arm Prospective Clinical Trial

Status Recruiting

Clinical Trial Summary

Explorative study, which evaluates the effect of Tislelizumab combined with chemotherapy in neoadjuvant treatment of stage Ⅲ unresectable non-small-cell lung carcinoma.

Clinical Trial Description

This is a open-label, single-arm prospective clinical trial to evaluate the efficacy and safety of Tislelizumab combined with chemotherapy in neoadjuvant treatment of newly diagnosed stage Ⅲ unresectable non-small cell lung cancer. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-small-cell Lung Cancer (NSCLC)

Clinical Trial Details

NCT number	NCT06357598
Study type	Interventional
Source	The Affiliated Hospital of Qingdao University
Contact
Status	Recruiting
Phase	Phase 4
Start date	January 18, 2024
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03725475` - A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
Completed	`NCT01874678` - A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer	N/A
Recruiting	`NCT02448992` - Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer	Phase 2/Phase 3
Completed	`NCT02113813` - A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations	Phase 1
Active, not recruiting	`NCT04338620` - Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC	Phase 2
Completed	`NCT06232967` - PPIO-006 Primary Tumor Resection for IVa NSCLC